Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The Bile Duct Cancer Therapeutics Market is Forecast to Decline up to 2019
By: Rajesh Gunnam
 
Jan. 19, 2012 - PRLog -- GlobalData estimates that the global bile duct cancer therapeutics market was worth $120.7m in 2011. It is forecast to decline at a CAGR of 4.6% for the next eight years to reach $112.6m by 2019. The current treatment options for bile duct cancer offer only symptomatic relief and are primarily dominated by generics and off-label drugs. The market declined during 2006-2011 owing to the patent expiry of Gemzar, which is also expected to leave the market vulnerable to generics. The decline during the forecast period can be attributed to the expected patent expiry of Xeloda.

GlobalData has found that the bile duct cancer therapeutics market has significant unmet need due to the limited efficacy and safety profiles of the currently market products. Consequently, there is significant potential for new entrants. The market is currently dominated by generics and off-label drugs. As the currently used chemotherapy regimens are injectable forms, there exists a significant unmet need in terms of compliance. Therefore, there is huge potential for products using new technology with better compliance and reduced adverse effects.

The currently used regimens for bile duct cancer have significant side effect concerns, such as alopecia, fatigue, thrombocytopenia and neutropenia. However, many patients are left with no choice other than the current products, which can provide some degree of disease alleviation. Therefore, the bile duct cancer therapeutics market is attractive, with a significant unmet need for a cure for the underlying cause of the disease. Developing new molecular targeted agents should lead to future blockbusters with the potential to capture major market shares. Consequently, there is a huge need for novel drugs with benefits over the well established existing products.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The bile duct cancer therapeutics market is underserved by the currently marketed drugs as no drug can provide a complete cure for the disease. The market offers huge potential for new entrants that can introduce drugs that can halt or reverse the disease progression and simultaneously offer good efficacy and safety profiles. There is also huge potential for novel therapies that can offer better symptomatic relief.

GlobalData’s analysis found that the bile duct cancer pipeline is weak as the majority of pipeline trials are sponsored by academic institutions and universities. The developmental pipeline for bile duct cancer consists of 23 molecules in different stages of development. All the molecules are first-in-class molecules with novel mechanisms of action compared to the drugs that are currently used for the treatment of bile duct cancer.

GlobalData, the industry analysis specialist, has released its new report, “Bile Duct Cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global bile duct cancer sector. The report identifies the key trends shaping and driving the global bile duct cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bile duct cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Bile...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.
End
Source:Rajesh Gunnam
Email:***@globaldata.com
Posted By:***@globaldata.com Email Verified
Zip:EC4Y 0AN
Tags:Bile Duct Cancer, Therapeutics, Pharmaceuticals_and_healthcare
Industry:Health
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
GlobalData News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share